Synthesis and in vitro cytotoxicity of novel hydrophilic chiral 2-alkoxy-1,4-butanediamine platinum (II) complexes

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 22, 2005, Pages 4936-4943

  Zhu, Haibin ^a   Cui, Kai ^a   Wang, Lianhong ^a   Gou, Shaohua ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antitumor drugs; Chiral 2 alkoxy 1,4 butanediamine; Platinum (II) complexes

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOBUTANE 1,1 DICARBOXYLATO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; CYCLOBUTANE 1,1 DICARBOXYLATO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; DICHLORO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; DICHLORO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; DICHLOROACETATE(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; DIGLYCOLATO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; DIGLYCOLATO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; GLYCOLATO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; GLYCOLATO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; MALONATO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; MALONATO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; OXALATO(ETHOXY 1,4 BUTANEDIAMINE)PLATINUM; OXALATO(METHOXY 1,4 BUTANEDIAMINE)PLATINUM; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HCT116; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

AMINES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 25844481568     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.08.025     Document Type: Article

References (38)

1. P.J. O'Dwyer, J. Steveson, and S.W. Johnson Clinical Status of Cisplatin, Carboplatin and Other Platinum Based Antitumor Drugs B. Lippert Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Verlag Helvetica Chimica Acta Zurich 31
2. R.B. Weiss, and M.C. Christian Drugs 46 1993 360
3. M. Kartalou, and J.M. Essigmann Mutat. Res. 478 2001 1
4. J.H. Burchenal, K. Kalaher, K. Dew, and L. Lokys Cancer Treat. Rep. 63 1979 1493
5. T.A. Conors, M.J. Cleare, and K.R. Harrap Cancer Treat. Rep. 63 1979 1499
6. R. Wilkinson, P.J. Cox, M. Jones, and K.R. Harrap Biochimie. 60 1978 851
7. D.B. Brown, A.R. Khokhar, M.P. Hacker, L. Lokys, J.H. Burchenal, R.A. Newmann, J.J. McCormack, and D. Frost J. Med. Chem. 25 1982 952
8. P. Lelieveld, W.J.F. Van der Vijgh, R.W. Veldhuizen, D. Van Velzen, L.M. Van Putten, G. Atassi, and A. Danguy Eur. J. Cancer Clin. Oncol. 20 1984 1087
9. A.H. Calvert, S.J. Harland, D.R. Newell, Z.H. Siddik, A.C. Jones, T.J. McElwain, S. Raju, E. Wiltshaw, I.E. Smith, J.M. Baker, M.J. Peckham, and K.R. Harrap Cancer Chemother. Pharmacol. 9 1982 140
10. B.J. Foster, K. Clagett-Carr, B. Leyland-Jones, and D. Hoth Cancer Treat. Rev. 12 1985 43
11. S.K. Carter, R. Canetta, and M. Rozencweig Cancer Treat. Rev. 12 1985 145
12. R. Canetta, M. Rosencweig, and S.K. Carter Cancer Treat. Rev. 12 1985 125
13. L.H. Wang, Y. Liu, S.H. Gou, and Q.D. You Huaxue Tongbao (Acta Chem.) 66 2003 828
14. L.H. Wang, Y. Liu, F.P. Yuan, Q.D. You, and S.H. Gou Chinese J. Inorg. Chem. 20 2004 775
15. H. Nowatari, Y. Kuroda, H. Hayami, K. Okamoto, H. Ekimoto, and K. Takahashi Chem. Pharm. Bull. 37 1989 2406
16. K. Morikawa, M. Honda, K. Endoh, T. Matsumoto, K. Akamatsu, H. Mitsui, and M. Koizumi J. Pharm. Sci. 80 1991 837
17. M. Noji, K. Okamoto, and Y. Kidani J. Med. Chem. 24 1981 508
18. E. Wong, and C.M. Giandomenico Chem. Rev. 99 1999 2451
19. A. Pasini, and F. Zunino Angew. Chem. Int. Ed. Engl. 26 1987 615
20. L.H. Wang, S.H. Gou, Y.J. Chen, and Y. Liu Bioorg. Med. Chem. Lett. 15 2005 3417
21. 2, 1981.
22. A.H. Haines, C. Morley, and B.A. Murrer J. Med. Chem. 32 1989 742
23. D.K. Kim, G. Kim, J. Gam, Y.B. Cho, H.T. Kim, J.H. Tai, K.H. Kim, W.S. Hong, and J.G. Park J. Med. Chem. 37 1994 1471
24. G. Odham, B. Pettersson, and E. Stenhagen Acta Chem. Scand. B 28 1974 36
25. M. Carmack, and C.J. Kelley J. Org. Chem. 33 1968 2171
26. L.J. Rubin, H.A. Lardy, and H.O.L. Fisher J. Am. Chem. Soc. 74 1952 425
27. 2: C, 54.28; H, 5.92. Found: C, 54.30; H, 6.04. (R)-2-Ethoxy-1,4-ditosylbutane was prepared in a similar manner and spectral data were identical with that of (S)-2-ethoxy-1,4- ditosylbutane.
28. A. Scheurer, P. Mosset, and R.W. Saalfrank Tetrahedron: Asymmetry 8 1997 1243
29. 2O).
30. S.C. Dhara Indian J. Chem. 8 1970 193
31. J. Reedijk, A.M.J. Fichtinger-Schepman, A.T. Van Oosteron, and P. Van de Putte Struct. Bonding 67 1987 53
32. S.J. Lippard Pure Appl. Chem. 59 1987 731
33. 2O (100 ml) was stirred at 60°C in the dark overnight. The resulting silver iodide was filtered through a pad of Celite. The filtrate was concentrated under a reduced pressure and white precipitate was collected and dried in vacuum.
34. 2O (20 ml). Under the nitrogen atmosphere the mixture was heated at 40°C for 24 h in the dark and filtered though a pad of Celite. Then disodium glycolate (2.0 mmol), sodium chloride (4.0 mmol) or sodium glycolate (4.0 mmol) aqueous solution was added to the above filtration. The resultant solution was then mixed with the above filtration and stirred at 40°C for 24 h. The reaction mixture was concentrated and ethanol was added before filtration. The filtrate was concentrated to afford yellow syrup, which gave a precipitate after addition of ether. The resulting precipitate was then filtered quickly to give a very hygroscopic solid.
35. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, and D. Vistica J. Natl. Cancer Inst. 83 1991 757
36. K.J. Mellish, L.R. Kelland, and K.R. Harrap Br. J. Cancer 68 1993 240
37. P. Skehan, R. Stroreng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107
38. M. Yang, Q.Y. Hu, L.R. Zhang, S.M. Zhu, J. Zou, R.C. Li, and K.S. Wang Afr. J. Chem. 50 1997 227